This device may enable miniaturization and new point-of-care applications in doctors' offices.
Researchers have created an ultrasensitive biosensor that could open up new opportunities for early detection of cancer and “personalized medicine” tailored to the specific biochemistry of individual patients. The device, which could be several hundred times more sensitive than other biosensors, combines the attributes of two distinctly different types of sensors, said Muhammad A. Alam, a Purdue Uni versity professor of electrical and computer engineering.The device — called a Flexure-FET biosensor — combines a mechanical sensor, which identifies a biomolecule based on its mass or size, with an electrical sensor that identifies molecules based on their electrical charge. The new sensor detects both charged and uncharged biomolecules, allowing a broader range of applications than either type of sensor alone.
The sensor has two potential applications: personalized medicine, in which an inventory of proteins and DNA is recorded for individual patients to make more precise diagnostics and treatment decisions; and the early detection of cancer and other diseases.
In early cancer diagnostics, the sensor makes possible the detection of small quantities of DNA fragments and proteins deformed by cancer long before the disease is visible through imaging or other methods, researchers said.
The sensor's mechanical part is a vibrating cantilever, a sliver of silicon that resembles a tiny diving board. Located under the canti lever is a transistor, which is the sensor's electrical part.
In other mechanical biosensors, a laser measures the vibrating frequency or deflection of the cantilever, which changes depending on what type of biomolecule lands on the cantilever. Instead of using a laser, the new sensor uses the transistor to measure the vibration or deflection.
The sensor maximizes sensitivity by putting both the cantilever and transistor in a “bias.” The cantilever is biased using an electric field to pull it downward as though with an invisible string. This pre-bending increases the sensitivity.
The transistor is biased by applying a voltage, maximizing its performance as well. A key innovation is the elimination of a component called a “reference electrode,” which is required for conventional electrical biosensors but cannot be miniaturized, limiting practical applications. This enables miniaturization and makes it feasible for low-cost, point-of-care applications in doctors' offices.
A U.S. patent application has been filed for the concept. The work has been funded by the U.S. Department of Defense, U.S. Department of Energy, National Institutes of Health-PRISM center at Purdue's Discovery Park, and the Semiconductor Research Consortium through the MSD center at the Massachusetts Institute of Technology.
This technology was done by Purdue University, West Lafayette, IN. For more information, visit www.purdue.edu.